Therapeutic apheresis in hematological and oncological diseases

Journal of Clinical Apheresis

Volumn 15, Issue 1-2, 2000, Pages 28-52

  Grima, Kathleen M ^a,b  

^a NEW YORK BLOOD CENTER   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOIMMUNIZATION; APHERESIS; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; BONE MARROW TRANSPLANTATION; CANCER THERAPY; ERYTHROCYTE APLASIA; ERYTHROCYTOSIS; HEMATOLOGIC DISEASE; HEMOCHROMATOSIS; HUMAN; LEUKOCYTOSIS; MYELOMA; PARAPROTEINEMIA; POLYCYTHEMIA VERA; SICKLE CELL ANEMIA; T CELL LYMPHOMA; THROMBOCYTOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0034069798     PISSN: 07332459     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1101(2000)15:1/2<28::AID-JCA4>3.0.CO;2-N     Document Type: Article

References (257)

1. Buckner CD, Clift RA, Sanders JE, et al. ABO-incompatible marrow transplants. Transplantation 1978;26:233-238.
2. Gale RP, Feig S, Ho W, et al. ABO blood group system and bone marrow transplantation. Blood 1977;52:185-194.
3. Berkman EM, Caplan S, Kim CS. ABO-incompatible bone marrow transplantation: Preparation by plasma exchange and in vivo antibody absorption. Transfusion 1977;18:504-508.
4. Bensinger WI, Baker DA, Buckner CD, et al. Immunoadsorption for removal of A and B blood-group antibodies. N Engl J Med 1981;304:160-162.
5. Warkentin PI, Yomtovian R, Hurd S, et al. Severe delayed hemolytic transfusion reaction complicating an ABO-incompatible bone marrow transplantation. Vox Sang 1983;45:40-47.
6. Bensinger WI, Buckner CD, Thomas ED, Clift RA. ABO-incompatible bone transplants. Transplantation 1982;33:427-429.
7. Lasky LC, Warkentin PI, Kersey JH, et al. Hemotherapy in patients undergoing blood group incompatible bone marrow transplantation. Transfusion 1983;23:277-22885.
8. Hershko C, Gale RP, Ho W, Fitchen J. ABH antigens and bone marrow transplantation. Br J Haematol 1980;44:65-73.
9. Braine HG, Sensenbrenner LL, Wright SK, et al. Bone marrow transplantation with major ABO blood group incompatibility using erythrocyte depletion of marrow prior to infusion. Blood 1982; 60:420-425.
10. Dinsmore RE, Reich LM, Kapoor N, et al. ABH incompatible bone marrow transplantation: removal of erythrocytes by starch sedimentation. Br J Haematol 1983;54:441-449.
11. Blacklock HA, Prentice HG, Evans JPM, et al. ABO-incompatible bone marrow transplantation : removal of red blood cells from donor marrow avoiding recipient antibody depletion. Lancet 1982;2:1061-1064.
12. Davis JM, Noga SJ, Braine H. Apheresis and hematopoietic progenitor cell processing. In: McLeod B, editor. Apheresis, principles and practice. Maryland: AABB Press; 1997. p 453-463.
13. Hows J, Beddow K, Gordon-Smith E, et al. Donor-derived red blood cell antibodies and immune hemolysis after allogeneic bone marrow transplantation. Blood 1986;67:177-181.
14. Sniecinski IJ, Petz LD, Oien L, Blume KG. Immunohematologic problems arising from ABO incompatible bone marrow transplantation. Transplant Proc 1987;19:4609-4611.
15. Sniecinski I: Management of ABO incompatibility in allogeneic bone marrow transplantation, in: Forman SJ, Blume KG, Thomas DL, editor. Bone marrow transplantation. Oxford: Blackwell Scientific Publications; 1994. p 497-503.
16. Murphy S. Polycythemia vera. In: Williams WJ, Beutler E, Erslev AJ, Lichtman MA, editors. Hematology. New York: McGraw-Hill; 1990. p 193-202.
17. Conley CL. Polycythemia vera. JAMA 1990;263:2481-2483.
18. Erslev AJ. Secondary polycythemia (erythrocytosis). In: Williams WJ, Beutler E, Erslev AJ, Lichtman MA, editors. Hematology. New York: McGraw-Hill; 1990. p 705-714.
19. Gerson SL, Lazarus HM. Hematopoietic emergencies. Semin Oncol 1989;16:532-542.
20. Perloff JK, Rosove MH, Child JS, Wright GB. Adults with cyanotic congenital heart disease: hematologic management. Ann Intern Med 1988;109:406-413.
21. West WO. Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period. South Med J 1987;80:323-327.
22. Brittenham GM. Disorders of iron metabolism: Iron deficiency and overload. In: Hoffman R, Benz EJ, Shattil SJ, et al., editors. Hematology, basic principles and practice. New York: Churchill Livingstone; 1995. p 492-523.
23. Kaboth U, Rumpf KW, Lipp T, et al. Treatment of polycythemia vera by large-volume erythrocytapheresis. Klin Wochenschr 1990;68:18-25.
24. Kevy SV. Extracorporeal therapy for infants and children. En: Petz L, Swisher SN, Kleinman S, et al., editors. Clinical practice of transfusion medicine. New York: Churchill Livingstone; 1996. p 733-755.
25. Boxer MA, Braun J, Ellman L. Thromboembolic risk of postsplenectomy thrombocytosis. Arch Surg 1978;13:808-809.
26. Chievitz E, Thiede T. Complications and causes of death in polycythemia vera. Acta Med Scand 1962;172:513-523.
27. Kessler Cm, Klein HG, Havlik RJ. Uncontrolled thrombocythemia in myeloproliferative disorders. Br J Haematol 1982;50:157-167.
28. Ablin AR. Managing the problem of hyperleukocytosis in acute leukemia. Am J Pediatr Hematol Oncol 1984;6:287-290.
29. van Buchem MA, te Velde J. Willemze R, Spaader PJ. Leucostatsis, an underestimated cause of death in leukaemia. Blut 1988;56: 39-44.
30. Creutzig U, Ritter J, Budde M, Sutor A, Schellong G, The German BFM Study Groups: early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Cancer 1987;60: 3071-3079.
31. Lester TJ, Johnson JW, Cuttner J. Pulmonary leukostasis as the single worst prognostic factor in patients with acute myelocytic leukemia and hyperleukocytosis. Am J Med 1985;79:43-48.
32. Lichtman MA. Rheology of leukocytes, leukocyte suspensions and blood in leukemia; possible relationship to clinical manifestations. J Clin Invest 1973;52:350-358.
33. Maurer HS, Steinherz PG, Gaynon PS, et al. The effect of initial management of hyperleukocytosis on early complications and outcome of children with acute lymphoblastic leukemia. J Clin Oncol 1988;6:1425-1432.
34. Radovic M, Balint B, Milenkovic L, Tiska-Rudman L, Taseski J. Therapeutic leukapheresis. Transfus Sci 1991;12:193-196.
35. Harris AL. Leukostasis associated with blood transfusion in acute myeloid leukaemia. Br Med J 1978;1:1169-1171.
36. Giachino O, Miniero R, Incarbone E, et al. Leukocytapheresis and exchange transfusion in the emergency treatment of hyperleukocytic acute lymphoblastic leukemia in children. Plasma Ther Transfus Technol 1988;9:365-368.
37. Nelson SC, Bruggers CS, Kurtzberg J, et al. Management of leukemic hyperleukocytosis with hydration, urinary alkalinazation, and allopurinol: are cranial irradiation and invasive cytoreduction necessary? Am J Pediatr Hematol Oncol 1993;15:351-355.
38. Ginsburg AD. Platelet function in patients with high platelet counts. Ann Intern Med 1975;82:506.
39. Moxey-Mims MM, Luban NLC, Bock GH, Ruley EJ, Preston KM. Relief of respiratory distress with leukapheresis in a child with chronic myelocytic leukemia. J Clin Apheresis 1988;4:47-49.
40. Fitzgerald D, Rowe JM, Heal J. Leukapheresis for control of chronic myelogenous leukemia during pregnancy. Am J Hematol 1986;22:213-218.
41. Hester JP, McCredie KB, Freireich EJ. Response to chronic leukapheresis procedures and survival of chronic myelogenous leukemia patients. Transfusion 1982;22:305-307.
42. Goldfinger D, Capostagno V, Lowe C, Sacks HJ, Gatti RA. Use of long-term leukapheresis in the treatment of chronic lymphocytic leukemia. Transfusion 1980;29:450-454.
43. Rossi PL, Alfano G, D'Onofrio G, Menichella G, Mango G. Depletion lymphocytapheresis in chronic lymphocytic leukemias:criteria for predicting which patients will respond to treatment. Int J Artif Organs 1986;9:59-62.
44. Frankel SR, Eardley A, Lauwers G. et al. The retinoic acid syndrome in acute promyelocytic leukemia. Ann Intern Med 1992; 117:292-296.
45. Nicholls RJ, Davies P, Kenwright MG. Thrombocytopenic purpura after blood transfusion. Br Med J 1970;2:581.
46. Shulman NR, Reid DM. Platelet Immunology. In: Coleman RW et al., editors. Hemostasis and thrombosis. Philadelphia: JB Lippincott; 1994. p 1860-1862.
47. Newman PJ, McFarland JG, Aster RH. Alloimmune Thrombocytopenias. In: Loscalzo J, Schafer AI, editors. Thrombosis and hemorrhage. Boston: Blackwell Scientific Publications; 1994. p 429-435.
48. Gerstner JB, Smith MJ, Davis KD, Cimo PL, Aster, RH. Post-transfusion purupra: therapeutic failure of HPA-1a negative platelet transfusion. Am J Hematol 1979;6:71-75.
49. Brecher ME, Moore SB, Lentendre L. Post-transfusion purupura: the therapeutic value of HPA-1a negative platelets.Transfusion 1990;30:433-435.
50. Win N, Peterkin MA, Watson WH. The therapeutic value of HPA-1a-negative platelet transfusion in post-transfusion purpura complicated by life-threatening haemorrhage. Vox Sang 1995; 69: 138-139.
51. Weisberg LJ, Linker CA. Prednisone therapy of post-transfusion purpura. Ann Intern Med 1984;100:76-77.
52. von dem Borne AED, Ouwehand WH. Immunology of platelet disorders. Bailleres Clin Haematol 1989;2:749-781.
53. Mueller-Eckhardt CH. Post-transfusion Purpura. Br J Haematol 1986;64:419.
54. Cunningham CC, Lind SE. Apparent response of refractory post-transfusion purpura to splenectomy. Am J Hematol 1989;30:112-113.
55. Cimo PL, Aster RH. Post-transfusion purpura: successful treatment by exchange transfusion. N Engl J Med 1972;287:290-292.
56. Abramson N, Eienberg PD, Aster RH. Post-transfusion purpura: immunologic aspects and therapy. N Engl J Med 1974;291:1163-1166.
57. Laursen B, Morling N, Rosenkvist J, et al. Post-transfusion purpura treated with plasma exchange by Haemonetics cell separator. Acta Med Scand 1978;203:539-543.
58. Erichson RB, Viles H, Grann V, et al. Post-transfusion purpura: case report with observation on antibody detection and therapy. Arch Intern Med 1978;138:998-999.
59. Eisenberg PD, Abramson N. Post-transfusion purpura: an enigma of alloimmunization. Am J Hematol 1980;9:331-336.
60. Mueller-Eckhardt C, Kuenzlen E, Pralle H. High-dose intravenous immunoglobulin for post-transfusion purpura. N Engl J Med 1983;308:287.
61. Motulsky AG. Frequency of sickling disorders in US blacks. N Engl J Med 1973;188:31-33.
62. Dean J, Schecter AN. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches. N Engl J Med 1978;229:752-763.
63. Alavi JB. Sickle cell anemia: pathophysiology and treatment. Med Clin North Am 1984;3:545-556.
64. Charache S. Treatment of sickle cell anemia. Annu Rev Med 1981;32:195-206.
65. Noguchi CT, Rodgers GP, Serjeant G, et al. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med 1988;318:96.
66. Charache S, Terrin ML, Moore RD. et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317-1322.
67. Schmalzer EA, Lee JO, Brown K, et al. Viscosity of mixtures of sickle and normal red cells at varying hematocrit levels. Implications for transfusion. Transfusion 1987;27:228-233.
68. Wayne AS, Kevy SV, Nathan DG. Transfusion management of sickle cell disease. Blood 1993;81:1109-1123.
69. Cohen AR, Martin MB, Silber JH, et al. A modified transfusion program for prevention of stroke in sickle cell disease. Blood 1992;79:1657-1661.
70. Adams R, McKie V, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. N Engl J Med 1998;339:5-11.
71. Kelin HG, Garner RJ, Miller DM, Rosen SL, Statham NJ, Winslow RM. Automated partial exchange in sickle cell anemia. Transfusion 1980;20:578-584.
72. Sarnaik S, Soorya D, Kim J, et al. Periodic transfusion for sickle cell anemia and CNS infarction. Am J Dis Child 1979;133:1254-1257.
73. Russel MO, Goldberg HI, Reis L, et al. Transfusion therapy for cerebrovascular abnormalities in sickle cell disease. J Pediatr 1979;88:382-387.
74. Kleinman SH, Hurvitz CG, Goldfinger D. Use of erythrocytopheresis in the treatment of patients with sickle cell disease. J Clin Apheresis 1984;2:170-176.
75. Rifkind S, Waisman J, Thompson R, et al. RBC exchange pheresis for priapism in sickle cell disease. JAMA 1979;242:2317-2318.
76. Weissman H, Nadel AJ, Dunn M. Simultaneous bilateral retinal arterial occlusions treated by exchange transfusion. Arch Opthalmol 1979;97:2151-2153.
77. Sheehy TW, Law DE, Wade BH. Exchange transfusion for sickle cell intrahepatic cholestasis. Arch Intern Med 1980;140:1364-1366.
78. Shao SH, Orringer EP. Sickle cell intrahepatic cholestasis: approach to a difficult problem. Am J Gastroenterology 1995;90: 2048-2050.
79. Morrison JC, Whybrew WD, Bucovaz ET. Use of parital exchange transfusion preoperatively in patients with sickle cell hemoglobinopathies. Am J Obstet Gynecol 1978;132:59-63.
80. Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. N Engl J Med 1995;333: 206-213.
81. Morrison JC, Wiser WL. The use of prophylactic partial exchange transfusion in pregnancies associated with sickle cell hemoglobinopathies. Obstet Gynecol 1983;62:419-424.
82. Cunningham FG, Pritchard JA, Mason R. Pregnancy and sickle cell hemoglobinopathies; results with and without prophylactic transfusion. Obstet Gynecol 1983;62:419-424.
83. Tuck SM, James CE, Brewster EM, Pearson TC, Studd JWW. Prophylactic blood transfusion in maternal sickle cell syndromes. Br J Obstet Gynaecol 1987;94:121-125.
84. Koshy M, Burd L, Wallace D, Moawad A, Baron J. Prophylactic red-cell transfusions in pregnant women with sickle cell disease: a randomized cooperative study. N Engl J Med 1988;319:1447-1452.
85. Morrison JC, Morrison FS. Prophylactic transfusions in patients with sickle cell disease (letter). N Engl J Med 1989;320:1286-1287.
86. Castro O, Finke-Castro H, Coats D. Improved method for automated red cell exchange in sickle cell disease. J Clin Apheresis 1986;3:93-99.
87. Cox JV, Steane E, Cunningham G, Frenkel EP. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Arch Intern Med 1988;148:2485-2489.
88. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin M. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990;322:1617-1621.
89. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. Blood 1990;76:1431-1437.
90. Phillips G, Slingluff C, Hartman J, Thomas P, Akwari O. Totally implantable intravenous catheters in the management of sickle cell anemia. Am J Hematol 1988;29:134-138.
91. Feinstein DJ, Rapaport SI, Chong MNY. Immunologic characterization of 12 factor VIII inhibitors. Blood 1969;34:85-90.
92. Ewenstein BM. Factor VIII and other coagulation factor inhibitors. In: Loscalzo J, Schafer AI, editors. Thrombosis and hemorrhage. Boston: Blackwell Scientific Publications, Inc.; 1994. p 729-747.
93. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981;45:200-203.
94. Lusher JM. Management of patients with factor VIII inhibitors. Transfus Med Rev 1987;1:123-130.
95. Brettler DB, Forsberg AD, Levine PH, et al. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII: a multicenter US experience. Arch Intern Med 1989;149:1381-1385.
96. Lusher JM. Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. Haemostasis 1996;26:124-130.
97. Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost 1997;78:1463-1467.
98. Gringeri A, Santagostino E, Mannucci PM. Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody. Haemostasis 1991;21:1-4.
99. Pflieger G, Boda Z, H'arsfalvi J, et al. Cyclosporin treatment of a woman with acquired hemophia due to factor VIII: C inhibitor. Postgrad Med J 1989;65:400-402.
100. Ewing NP, Sanders NL, Dietrich SL, Kasper CK. Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors. JAMA 1998;259:65-68.
101. Wensley RT, Stevens RF, Burn AM, et al. The role of intensive plasma exchange in the prevention and management of haemorrhage in patients with inhibitors to factor VIII. BMJ 1980;281: 1388-1389.
102. Slocombe GW, Newland AC, Colvin MP, et al. The role of intensive plasma exchange in the prevention and management of haemorrhage in patients with inhibitors to favor VIII. Br J Hematol 1981;47:577-585.
103. Cobcroft R, Tamagnini G, Dormandy KM. Serial plasmapheresis in a haemophiliac with antibodies to FVIII. J Clin Path 1977;30: 763-765.
104. Smith SV, Liles DK, White GC, Brecher ME. Successful treatment of transient acquired factor X deficiency by plasmapheresis with concomitant intravenous immunoglobulin and steroid therapy. Am J Hematol 1998;57:245-252.
105. Fu Yang-Xin, Kaufman R, Rudolph AE, et al. Multimodality therapy of an acquired factor V inhibitor. Am J Hematol 1996; 51:315-318.
106. Colwell NS, Tollefsen DM, Blinder MA. Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder. Br J Haematol 1997;97:219-226.
107. Bona RD, Pasquale DN, Kalish RI, et al. Porcine factor VIII and plasmapheresis in the management of hemophilia patients with inhibitors. Am J Hematol 1986;21:201-207.
108. Pintado T, Taswell HF, Bowie EJW. Treatment of life-threatening hemorrhage due to acquired factor VIII inhibitor. Blood 1975;46: 535-541.
109. Pineda AA. Therapeutic applications of plasma exchange and cytapheresis. In: Hamburger HA, Batsakis JG, editors. Clinical laboratory annual. Norwalk, CT: Appleton-Century-Crofts; 1983. vol 2, p 145-174.
110. Nilsson IM, Berntorp E, Zettervoll O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988;318:947-950.
111. Nilsson IM, Sundqvist SB, Freiburghaus C. Extracorporeal protein A-sepharose and specific affinity chromatography for removal of antibodies. Prog Clin Biol Res 1984;150:225-241.
112. Uehlinger J, Button GR, McCarthy JM, Forster A, Watt R, Aledort LM. Immunoadsorption for coagulation factor inhibitors. Transfusion 1991;31:265-269.
113. Gjorstrup P, Berntorp E, Larsson L, Milsson IM. Kinetic aspects of the removal of IgG and inhibitors in hemophiliacs using protein A immunoadsorption. Vox Sang 1991;61:244-250.
114. Smith OP, Hann IM. rVIIa therapy to secure haemostasis during central line insertion in children with high-responding FVIII inhibitors. Br J Haematol 1996;92:1002-1004.
115. Young N. Aplastic anemia: research themes and clinical issues. Prog Hematol 1981;12:227-273.
116. Silver BJ, Zuckerman KS. Aplastic anemia: recent advances in pathogenesis and treatment. Med Clin North Am 1980;64:607-629.
117. Kranz SB. New therapies for aplastic anemia. Am J Med Sci 1986;291:371-379.
118. Young N, Griffith P, Brittain E, et al. A multicenter trail of antithymocyte globulin in aplastic anemia and related diseases. Blood 1988;72:1861-1869.
119. Leonard EM, Raefsky ER, Griffith P, Kimball J, Nienhuis, AW, Young NS. Cyclosporine therapy of aplastic anemia, congenital and acquired red cell aplasia. Br J Haematol 1989;72:278-284.
120. Means RT, Jr, Dessypris EN, Krantz SB. Treatment of refractory pure red cell aplasia with cyclosporine A. disappearance of IgG inhibitor associated with clinical response. Br J Haematol 1991; 78:114-119.
121. Kranz SB, Acquired pure red cell aplasia. In: Hoffman R, Benz EJ, Shattil SJ, et al., editors. Hematology, basic principles and practice, New York: Churchill Livingstone; 1995. p 350-362.
122. Abdou NI. Plasma exchange in the treatment of aplastic anemia. In: Tindall RAS, editor. Therapeutic apheresis and plasma perfusion. New York: Alan R. Liss, Inc., 1982. p 337-346.
123. Young NS, Klein HG, Griffith P, et al. Therapeutic plasma exchange and lymphocyte depletion in aplastic anemia and pure red cell aplasia. In: Nose Y, Malchesky PS, Smith JW, et al., editors. Plasmapheresis. New York: Raven Press, 1983. p 339-347.
124. Fitchen JJ, Cline MJ, Saxon A. et al. Serum inhibitors of hematopoiesis in a patient with aplastic anemia and systemic lupus erythematosus. Am J Med 1979;6:537-542.
125. Messner HA, Fauser AA, Curtis JE, et al. Control of antibody-mediated pure red-cell aplasia by plasmapheresis. N Engl J Med 1981;304:1334-1338.
126. Freund LG, Hippe E, Strandgaard S, Pelus LM, Erslev AJ. Complete remission in pure red aplasia after plasmapheresis. Scand J Haematol 1985;35:351-358.
127. Khelif A, Van HV, Tremisi JP, et al. Remission of acquired pure red cell aplasia following plasma exchanges. Scand J Haematol 1985;35:13-17.
128. Berlin G, Lieden G. Longterm remission of pure red cell aplasia after plasma exchange and lymphocytopheresis. Scand J Haematol 1986;36:121-122.
129. Harris JW. Parvovirus B19 for the hematologist. Am J Hematol 1992;39:119-130
130. Wilson LD, Kacinski BM, Edelson RL, Heald PW. Cutaneous T-cell lymphomas. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer, principles and practice of oncology. New York: Lippincott-Raven; 1997. p 2220-2232.
131. Heald RW, Edelson RL. Cutaneous T-cell lymphoma. In: Hoffman RH, Benz EJ, Shattil SJ et al., editors. Hematology, basic Principles and practice. New York; Churchill Livingstone; 1995. p 1332-1344.
132. Lim HW, Edelson R. Photopheresis for the treatment of cutaneous T-cell lymphomal In: Koh HK, Foss FM, editors. Cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9:1117-1126.
133. Edelson R, Heald P, Perez M, et al. Photopheresis update. Prog Dermatol 1991;25:1-6.
134. Duvic M, Hester JP, Lemak NA. Photopheresis for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996;35:573-9.
135. Gottlieb SL, Wolfe JT, Fox FE, et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol 1996;35: 946-57.
136. Zic JA, Stricklin GP, Greer JP, et al. Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol 1996;35:935-945.
137. Bongiovanni MB, Katz RS, Tomaszewski JE, et al. Cytapheresis in a patient with Sezary syndrome. Transfusion 1981;21:332.
138. Edelson R, Facktor M, Andrews A, et al. Successful management of the Sezary syndrome. N Engl J Med 1974;291:293.
139. Pineda AA, Brzica SM, Taswell HF. Continuous- and semicontinuous-flow blood centrifugation systems: therapeutic applications with plasma-, platelet-, lympha-, and eosinapheresis. Transfusion 1977;17:407-416.
140. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy, N Engl J Med 1987;316:297.
141. Alverson DC, Izquierdo LA. Hemolytic disease of the newborn: treatment and prevention. In Rossi EC, Simon TL, Moss GS, Gould SA, editors. Principles of transfusion medicine. Baltimore: Williams & Wilkins; 1996. p 127-140.
142. Bowman JM. Intrauterine and neonatal transfusion. In: Anderson KC, Ness PM, editors. Scientific basis of transfusion medicine, implications for clinical practice. Philadelphia: W.B. Saunders Co.; 1994. p 403-420.
143. Mollison PL, Engelfriet CP, Contreras M. Haemolytic disease of the fetus and newborn. In: Blood transfusion in clinical medicine. London: Blackwell Science Ltd.; 1997. p 390-424.
144. Rock G. Plasma exchange in the treatment of rhesus hemolytic disease: review. Plasma Ther Transfusion Technol 1981;2:211-225.
145. Filbey D, Berseus O, Lindelberg S, Wesstrom G. A management programme for Rh alloimmunization during pregnancy. Early Hum Dev 1987;15:11-20.
146. Watson WJ, Katz VL, Bowes WA. Plasmapheresis during pregnancy. Obstet Gynecol 1990;76:451-457.
147. Shirey R, Ness P, Kickler T, et al. The association of anti-P and early abortion. Transfusion 1987;27:189-191.
148. Furukawa K, Nakajima T, Kogure T, et. al. Example of a woman with multiple intrauterine deaths due to anti-M who delivered a live child after plasmapheresis. Exp Clin Immunogenet 1993;10: 161-167.
149. Yoshida H, Ito K, Kusakari T, et. al. Removal of maternal antibodies from a woman with repeated fetal loss due to P blood group incompatibility. Transfusion 1994;34:702-705.
150. Rock G, Lafreniere I, Chan L, McCombie N. Plasma exchange in the treatment of hemolytic disease of the newborn. Transfusion 1981;21:546-551.
151. Berlin G, Selbing A, Gottvall T. Plasma exchange and high dose IV immunoglobulin in the treatment of severe rhesus hemolytic disease. Prog Clin Biol Res 1990;337:337-340.
152. Klein HG, Faltz LL, McIntosh CL, et al. Surgical hypothermia in a patient with a cold agglutinin: management by plasma exchange. Transfusion 1980;20:354-370.
153. Steane EA, Sheehan RG, Brooks BD, et al. Therapeutic plasmapheresis in patients with antibodies to high-frequency red cell antigens. In: Tindall RSA, editor. Therapeutic Apheresis and Plasma Perfusion. New York: Alan R. Liss, Inc.; 1982. p 347-353.
154. Gmur JP, Burger J, Schaffner A, et al. Pure red cell aplasia of long duration complicating major ABO incompatible bone marrow transplantation. Blood 1990;75:290-295
155. Kickler TS. The challenge of platelet alloimmunization: management and prevention. Transfusion 1990;14:8-18.
156. Slichter, Sherrill J. Principles of platelet transfusion therapy. In: Hoffman R, Benz EJ, Sanford AJ, et al., editors. Hematology, basic priniciples and practice. New York: Churchill Livingstone; 1995. p 1987-2006.
157. Daly PA, Schiffer CA, Aisner J, Wiernik PH. Platelet transfusion therapy: one-hour post-transfusion increment are valuable in predicting the need for HLA-matched preparations. JAMA 1980;243: 435-438.
158. O'Connell B, Lee EJ, Schiffer CA. The value of 10-minute post-transfusion platelet counts. Transfusion 1988;28:66-67.
159. Bishop JF, Matthews JP, McGrath K, Yuen K, Wolf MM, Szer J. Factors influencing 20-hour increments after platelet transfusion. Transfusion 1991;31:392-396.
160. Gmur J, von Felten A, Osterwalder B, et al. Delayed alloimmunization using random single donor platelet transfusions: a prospective study in thrombocytopenic patients with acute leukemia. Blood 1983;62:473-479.
161. Lane TA, Anderson KC, Goodnough LT, et al. Leukocyte reduction in blood component therapy. Ann Intern Med 1992;117:151-162.
162. Andreu G, Dewailly J, Leberre C, et al. Prevention of HLA alloimmunization with leukocyted-poor packed red cells and platelet concentrates obtained by filtration. Blood 1988;72:964-969.
163. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337:1861-9.
164. Yankee RA, Grumet FC, Rogentine GN. Platelet transfusion therapy: the selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing. N Engl J Med 1969;281: 1208-1212.
165. Lohrman H-P, Bull MI, Decter JA, Yankee RA, Graw RG. Platelet transfusions from HLA compatible unrelated donors to alloimmunized patients. Ann Intern Med 1974;80:9-14.
166. O'Connell BA, Schiffer CA. Donor selection for alloimmunized patients by platelet crossmatching of random-donor platelet concentrates. Transfusion 1990;30:314-317.
167. Lee EJ, Norris D, Schiffer CA. Intravenous immune globulin for patients alloimmunized to random donor platelet transfusions. Transfusion 1987;27:245.
168. Kickler T, Braine HG, Piantadosi S, et. al. A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients. Blood 1987;70:313.
169. Ziegler ZR, Shadduck RK, Rosenfeld CS et. al. High-dose intravenous gamma globulin improves responses to single-donor platelets in patients refractory to platelet transfusion. Blood 1987;70: 1433.
170. Bensinger WI, Buckner CD, Clift RA, Slichter SJ, Thomas ED. Plasma exchange for platelet alloimmunization. Transplantation 1986;41:602-605.
171. Christie DJ, Howe RB, Lennon SS, Sauro SC. Treatment of refractoriness to platelet transfusion by protein A column therapy. Transfusion 1993;33:234-242.
172. Kim HC, Dugan NNP, Synder HW, Bunin N. Protein A immunoadsorption treatment in children with refractoriness to platelet transfusion (RPT). Blood 1992;80:222a.
173. Hussein MA, Long T, Bolwell B, et al. Response to Prosorba A column in alloimmunized platelet refractory patients. Transfusion 1994;34:66S.
174. Lopez-Plaza I, Miller K, Leitman SF. Ineffectiveness of protein A adsorption in the treatment of platelet refractoriness. J Clin Apheresis 1992;7:33.
175. Kruskall MS. The perils of platelet transfusions. N Engl J Med 1997;337:1914-15.
176. Moake JL. Studies on the pathophysiology of thrombotic thrombocytopenic purpura. Semin Hematol 1997;34:83-9.
177. Asada Y, Sumiyoshi A, Hayashi T, et al. Immunohistochemistry of vascular lesions in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thrombosis Res 1985;38:469-479.
178. Moake JL, McPherson PD. Abnormalities of von Willebrand factor multimers in thrombotic thrmobocytopenic purpura and the hemolytic-uremic syndrome. Am J Med 1989;87:3-9N.
179. Furlan M, Robles R, Solenthaler M, Lammie B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic throbocytopenic purpura. Blood 1998;91:2839-2846.
180. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-84.
181. Tsai H-M, Lian EC-Y. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-94.
182. Moake JL. Moschcowitz, multimers, and metalloprotease. N Engl J Med 1998;339:1629-31.
183. Cohen JA, Brecher ME, Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apheresis 1998;13:16-19.
184. Bennett CL, Weinberg PD, Rozenberg-Ben-Dor K et al. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med 1998;128:541-544.
185. Hymes KB, Karpatkin S. Human Immunodeficiency Virus Infection and Thrombotic Microangiopathy. Semin Hematol 1997;34: 117-125.
186. Leaf AN, Laubenstein LJ, Raphael B. Thrombotic thrombocytopenic purpura associated with human immnuodeficiency virus type I (HIV-I) infection. Ann Intern Med 1988;109:194-197.
187. Rarick MU, Espina B, Mocharnuk R et al. Thrombotic thrombocytopenic purpura in patients with human immunodeficiency virus infection: a report of three cases and review of the literature. Am J Hematol 1992;40:103-109.
188. Keusch GT, Acheson DWK. Thrombotic thrombocytopenic purpura associated with Shiga toxins. Semin Hematol 1997;34:106-116.
189. Torok TJ, Holman RC, Chorba TL. Increasing mortality from thrombotic thrombocytopenic purpura in the United States: analysis of national mortality data, 1968-1991. Am J Hematol 1995; 50:84-90.
190. Julius CJ, Dunn ZL, Blazina JF. HELLP syndrome: laboratory parameters and clinical course in four patients treated with plasma exchange. J Clin Apheresis 1994;9:228-235.
191. Weiner CP. Thrombotic microangiopathy in pregnancy and the postpartum period. Semin Hematol 1987;24:119-129.
192. McCrae KR, Cines D. Thrombotic microangiopathy during pregnancy. Semin Hematol 1997;34:148-158.
193. Nesher G, Hanna VE, Morre TL, et al. Thrombotic microangiopathic hemolytic anemia in systemic lupus erythematosis. Semin Arth Rheum 1994;24:165-172.
194. Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 1994;14: 495-504.
195. Wiener Y, Nakhleh RE, Lee MW. Prognostic factors and early resumption of cyclosporin A in renal allograft recipients with thrombotic microangiopathy and hemolytic uremic syndrome. Clin Transplant 1997;11:157-62.
196. Gharpure VS, Devine SM, Holland HK, et al. Thrombotic thrombocytopenic purpura associated with FK506 following bone marrow transplantation. Bone Marrow Transplant 1995;16:715-716.
197. Schriber JR, Herzig GP. Transplantation-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 1997;34:126-133.
198. Kalhs P, Brugger S, Schwarzinger I, et al. Microangiopathy following allogeneic marrow transplantation. Transplantation 1995; 60:949-957.
199. Zeigler ZR, Shadduck RK, Nemunaitis J, et al. Bone marrow transplant-associated thrombotic microangiopathy: a case series. Bone Marrow Transplant 1995;15:247-253.
200. Silva VA, Frei-Lahr, Brown RA, et al. Plasma exchange and vincristine in the treatment of hemolytic uremic syndrome/ thrombotic thrombocytopenic purpura associated with bone marrow transplantation. J Clin Apheresis 1991;6:16-20.
201. Sarode R, McFarland JG, Flomenber N. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant 1995;16:271-275.
202. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thombocytopenic purpura: outcome with plasma exchange. N Engl J Med 1991;325:393-397.
203. Obrador GT, Zeigler ZR, Shadduck RK, et al. Effectiveness of cryosupernatant therapy in refractory and chronic relapsing thrombotic thrombocytopenic purpura. Am J Hematol 1993;42: 217-220.
204. Rock G, Shumak KH, Sutton DM, et al. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Br J Haematol 1996;94:383-386.
205. Laurence J, Mitra D, Steiner M, et al. Plasma from patients with idiopathic and human immunodeficiency virus-associated thrombotic thrombocytopenic purpura induces apoptosis in microvascular endothelial cells. Blood 1996;87:3245-3246.
206. Harrison CN, Lawrie AS, Iqbal A, et al. Plasma exchange with solvent/detergent-treated plasma of resistant thrombotic thrombocytopenic purpura. Br J Haematol 1996;94:756-758.
207. Moake J, Chintagumpala M, Turner N, et al. Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura. Blood 1994;84:490-497.
208. Kwaan HC, Soff GA. Mangement of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 1997;34:159-166.
209. Gordon LI, Kwaan HC, Rossi EC. Deleterious effects of platelet transfusions and recovery thrombocytosis in patients with thrombotic microangiopathy. Semin Hematol 1987;24:194-201.
210. Bell WR, Braine HG, Ness P, et al. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: clinical experience in 108 patients. N Engl J Med 1991;325:398-403.
211. Bukowski RM. Thrombotic thrombocytopenic purpura: a review. Prog Hematol Thromb 1982;6:2287-337.
212. Rosove MH, Ho WG, Goldfinger D. Ineffectiveness of aspirin and dipyridamole in the treatment of thrombotic thrombocytopenic purpura. Ann Intern Med 1982;96:27.
213. Shumak KH, Rock GA, Nair RC. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Ann Intern Med 1995;122:569-572.
214. Gutterman LA, Stevenson TD. Treatment of thrombotic thrombocytopenic purpura with vincristine. JAMA 1982;247:1433.
215. Onundarson PT, Rowe JM, Heal JM, Francis CW. Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura. Arch Intern Med 1992;152:791-796.
216. Crowther MA, Heddle N, Hayward CP, et. al. Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura. Ann Intern Med 1996;125: 294-296.
217. Gaddis TG, Guthrie TH, Drew MJ, et al. Treatment of plasma refractory thrombotic thrombocytopenic purpura with protein A immunoabsorption. Am J Hematol 1997;55:55-8.
218. Centurioni R, Bobbio-Pallavicini E, Porta C, et al. Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins: results in 17 patients. Haematologica 1995;80:325-31.
219. Hand JP, Lawlor ER, Yong CKK, Davis J. Successful use of cyclosporine A in the treatment of refractory thrombotic thrombocytopenic purpura. Br J Haematol 1998;100:597-599.
220. Moake JL. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. In: Hoffman R, Benz EJ, Shattil SJ, et al., editors. Hematology basic principles and practice. New York: Churchill Livingstone, Inc.; 1995. p 1879-1889.
221. Salmon SE, Cassady RJ. Plasma cell neoplasms. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology, New York: Lippincott-Raven; 1997. p 2344-2386.
222. Kyle RA. Multiple myeloma and other plasma cell disorders. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, editors. Hematology, basic principles and practice. New York: Churchill Livingstone; 1995. p 1354-1374.
223. Cohen DJ, Sherman WH, Osserman EF, et al. Acute renal failure in patients with multiple myeloma. Am J Med 1984;76Z:247-256.
224. Defronzo RA, Cooke CR, Wright Jr, et al. Renal function in patients with multiple myeloma. Medicine (Baltimore) 1978;57: 151-166.
225. Bernstein SP, Humes HD. Reversible renal insufficient in multiple myeloma. Arch Intern Med 1982;142:2083-2086.
226. Hamblin TJ. The kidney in myeloma. BMJ 1986;2:292.
227. Solomon A, Weiss DT, Kattine AA. Nephrotoxic potential of Bence-Jones proteins. N Engl J Med 1991;324:1845-1851.
228. Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Arch Intern Med 1990;150:1693-1695.
229. Bachrach HJ, Myers JB, Bartholomew WR. A unique case of kappa light-chain disease associated with cryoglobulinemia, pyroglobulinemia, and hyperviscosity syndrome. Am J Med 1989; 86:596-602.
230. Carter PW, Cohen HJ, Crawford J. Hyperviscosity syndrome in association with kappa light chain myeloma. Am J Med 1989;86: 591-595.
231. McGrath MA, Penny R. Paraproteinemias: blood hyperviscosity and clinical manifestations. J Clin Invest 1976;58:1155-1162.
232. Bergsagel D. Macroglobulinemia. In: Williams WJ, Beutler E, Ersler AJ, Lichtman MA, editors. Hematology, 4th edition. New York: McGraw Hill Publishing Company; 1990. chap 123, p 1141-1145.
233. Misiani R, Tiraboschi G, Mingardi G, Mecca G. Management of myeloma kidney: an anti-light chain approach. Am J Kidney Dis 1987;10:28-33.
234. Russell JA, Fitzharris BM, Corringham, et al. Plasma exchange versus peritoneal dialysis for removing Bench-Jones. BMJ 1978; 2:1397.
235. Bear RA, Cole EH, Slang A, et al. Treatment of acute renal failure due to myeloma kidney. Can Med Assoc J 1980;123:750-753.
236. Johnson WJ, Kyle RA, Dahlberg PJ. Dialysis in the treatment of multiple myeloma. Mayo Clin Proc 1980;55:65-72.
237. Solling K, Solling J. Clearances of Bench-Jones proteins during peritoneal dialysis or plasmapheresis in myelomatosis associated with renal failure. Contr Nephrol 1988;68:259-262.
238. Crawford J, Cox EB, Cohen HJ. Evaluation of hyperviscosity in monoclonal gammopathies. Am J Med 1985;79:13-20.
239. Reinhart WH, Lutolf O, Nydegger U, Mahler F, Straub PW. Plasmapheresis for hyperviscosity syndrome in macroglobulinemia Waldenstrom and multiple myeloma: influence on blood rheology and the microcirculation. J Lab Clin Med 1992;119:69-76.
240. Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 1990;150:863-869.
241. Zucchelli P, Pasquali S, Cagnoli L, Rovinetti C. Plasma exchange therapy in acute renal failure due to light chain myeloma. Trans Am Soc Artif Intern Organs 1984;30:36-39.
242. Krogstad DJ. Plasmodium species (malaria). In: Mandel D, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. New York: Churchhill Livingstone; 1995. p 2415-2426.
243. Field JW. The morphology of malarial parasites in thick blood films. IV. The identification of species and phase. Trans R Soc Trop Med Hyg 1941;34:405-14.
244. Vachon F, Wolff M, Lebras J. Exchange transfusion as an adjunct to the treatment of severe falciparum malaria. Clin Inf Dis 1992; 14:1269.
245. Gelfand JA. Babesia. In: Mandel D, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. New York: Churchhill Livingstone; 1995. p 2497-2500.
246. Boustani MR, Lepore TJ, Gelfand JA, Lazarus DS. Acute respiratory failure in patients treated for babesiosis. Am J Respir Crit Care Med 1994;149:1689-91.
247. Miller KD, Greenberg AE, Campbell CC. Treatment of severe malaria in the United States with a continuous infusion of quinidine gluconate and exchange transfusion. N Engl J Med 1989; 321:65-70.
248. White NJ. The treatment of malaria. N Engl J Med 1996;335:800-806.
249. Cahill KM, Benach JL, Reich LM, et al. Red cell exchange: treatment of babesiosis in a splenectomized patient. Transfusion 1981; 21:193-198.
250. Jacoby GA, Hunt JV, Kosinski KS, et al. Treatment of transfusion-transmitted babesiosis by exchange transfusion. N Engl J Med 1980;303:1098-1100.
251. Machtinger L, Telford SR, Inducil C. Treatment of babesiosis by red blood cell exchange in an HIV-positive, splenectomized patient. J Clin Apheresis 1993;8:78-81.
252. Evenson DA, Perry E, kloster B, et al. Therapeutic apheresis of babesiosis. J Clin Apheresis 1998;13:32-36.
253. Phillips P, Nantel S, Benny WB. Exchange transfusion as an adjunct to the treatment of severe falciparum malaria: case report and review. Rev Infect Dis 1990;12:1100-1108.
254. Lercari G, Pganinin G, Malfanti L, et al. Apheresis for severe malaria complicated by cerebral malaria, acute respiratory distress snydrome, acute renal failure, and disseminated intravascular coagulation. J Clin Apheresis 1991;7:93-96.
255. Wallach Mr., Al Mahroos GM. Exchange transfusion of malaria: what are the indications? Rev Infect Dis 1991;13:763.
256. Saddler M, Barry M. Treatment of severe malaria by exchange transfusion. N Engl J Med 1990;322:58.
257. Wong RD, Murthy AR, Mathisen GE et al. Treatment of severe falciparum malaria during pregnancy with quinidine and exchange transfusion. Am J Med 1992;92:561-562.